ArticlePain reports2026
Impact of chronic pain on the families of U.S. adults.
Article in Pain reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Introduction: Chronic pain (CP) can profoundly strain family systems, yet few population studies have explored prevalence and population dynamics of CP with high impact on families. Objectives: Examining prevalence and phenomenological characteristics of chronic pain with high impact on the families of U.S. adults. Situating HICP-family within a tiered cascade of functional impact. Methods: Prevalence estimated using 2023 National Health Interview Survey Data (n = 29,522). Results: Findings are as follows: (1) the population prevalence of CP with high impact on families (high-impact chronic pain [HICP]-Family) is 4.4% among U.S. adults, 18.1% among U.S. adults with CP, and 46.3% among U.S. adults with HICP; (2) HICP-Family is almost exclusively reported by those who have HICP that limits their individual functioning in life and work, yet most of those with HICP do not report concomitant HICP-Family; (3) among U.S. adults reporting both HICP and HICP-Family, the prevalence of clinically significant anxiety/depression symptoms is 46.1%; (4) among all U.S. adults with clinically significant anxiety/depression symptoms, the prevalence of HICP and concomitant HICP-Family is 14.9%. Conclusion: The need to develop effective supports and promote adaptive resilience in families highly affected by CP is clear. Clinical tools to support person-centered assessment of family and relational functioning, development of effective family-level interventions for U.S. adults, and collaborative models of care are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.